Yuen MF - Search Results

1

JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B.

Gane E, Yuen MF, Kakuda TN, Ogawa T, Takahashi Y, Goeyvaerts N, Lonjon-Domanec I, Vaughan T, Schluep T, Hamilton J, Njumbe Ediage E, Hillewaert V, Snoeys J, Lenz O, Talloen W, Biermer M. Gane E, et al. Among authors: yuen mf. Antivir Ther. 2022 Jun;27(3):13596535221093856. doi: 10.1177/13596535221093856. Antivir Ther. 2022. PMID: 35695169 Free article. Clinical Trial.

2

Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine.

Yuen MF, Wong DK, Sablon E, Yuan HJ, Sum SM, Hui CK, Chan AO, Wang BC, Lai CL. Yuen MF, et al. Antivir Ther. 2003 Dec;8(6):531-4. Antivir Ther. 2003. PMID: 14760886

3

One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.

Wong DK, Yuen MF, Ngai VW, Fung J, Lai CL. Wong DK, et al. Among authors: yuen mf. Antivir Ther. 2006;11(7):909-16. Antivir Ther. 2006. PMID: 17302253 Clinical Trial.

4

A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B.

Yuen MF, Kim J, Kim CR, Ngai V, Yuen JC, Min C, Kang HM, Shin BS, Yoo SD, Lai CL. Yuen MF, et al. Among authors: yuen jc. Antivir Ther. 2006;11(8):977-83. Antivir Ther. 2006. PMID: 17302367 Clinical Trial.

5

Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment.

Yuen MF, Sablon E, Libbrecht E, Van De Velde H, Wong DK, Fung J, Wong BC, Lai CL. Yuen MF, et al. Antivir Ther. 2006;11(6):779-86. Antivir Ther. 2006. PMID: 17310822 Clinical Trial.

6

Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population.

Fung J, Lai CL, Yuen JC, Wong DK, Tanaka Y, Mizokami M, Yuen MF. Fung J, et al. Among authors: yuen jc, yuen mf. Antivir Ther. 2007;12(1):41-6. Antivir Ther. 2007. PMID: 17503746

7

Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.

Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, Wong BC, Fung J, Yuen JC, Lai CL. Yuen MF, et al. Among authors: yuen jc. Antivir Ther. 2007;12(8):1295-303. Antivir Ther. 2007. PMID: 18240869 Clinical Trial.

8

Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.

Yuen MF, Fung J, Seto WK, Wong DK, Yuen JC, Lai CL. Yuen MF, et al. Among authors: yuen jc. Antivir Ther. 2009;14(5):679-85. Antivir Ther. 2009. PMID: 19704171 Clinical Trial.

9

Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease.

Yuen MF, Han KH, Um SH, Yoon SK, Kim HR, Kim J, Kim CR, Lai CL. Yuen MF, et al. Hepatology. 2010 Mar;51(3):767-76. doi: 10.1002/hep.23462. Hepatology. 2010. PMID: 20091678 Clinical Trial.

10

Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir.

Seto WK, Liu K, Fung J, Wong DK, Yuen JC, Hung IF, Lai CL, Yuen MF. Seto WK, et al. Among authors: yuen jc, yuen mf. Antivir Ther. 2012;17(7):1255-62. doi: 10.3851/IMP2335. Epub 2012 Sep 6. Antivir Ther. 2012. PMID: 22951420

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

618 results

Search Page

Filters